✨ Free AI Report
GSK plc: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research GSK plc
Company Research

GSK plc: Business Overview, Financials & Competitive Analysis

GSK plc scores 7/10 on the AskCyborg Cyborg Score (Strong). Diversified vaccine and specialty pharma leader with strong pipeline momentum and acquisition strategy well-positioned to drive sustainable growth. GSK demonstrates strong fundamentals as a top-10 global pharmaceutical company with a $118B market cap and robust pipeline of 64 vaccines and specialty medicines. Recent acquisitions (RAPT Therapeutics, Syndivia) and strategic pipeline.

What is GSK plc's industry? GSK plc (gsk.com) operates in Pharmaceutical and Biotechnology. AskCyborg classifies GSK plc under Pharmaceutical and Biotechnology in its company registry.

GSK plc is a British multinational pharmaceutical and biotechnology company that discovers, develops, and delivers medicines and vaccines. In the pharmaceutical industry, GSK ranks as one of the largest firms by total...

7/ 10Strong

Cyborg Score thesis

Diversified vaccine and specialty pharma leader with strong pipeline momentum and acquisition strategy well-positioned to drive...

Read the full analyst-debate transcript →
Industry Pharmaceutical and Biotechnology
5 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest GSK plc Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for GSK plc

AskCyborg analysts argue the bull and bear cases for GSK plc across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
GSK plc OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

GSK plc Overview

Pro stress-test →

GSK plc is a British multinational pharmaceutical and biotechnology company that discovers, develops, and delivers medicines and vaccines. In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company maintains a diversified portfolio spanning specialty medicines, vaccines, and consumer health products across major therapeutic areas.

Strategic Profile

Pro stress-test →

GSK's R&D pipeline currently includes 64 vaccines and specialty medicines in its four core therapeutic areas of infectious diseases, HIV, oncology and immunology/respiratory. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology. In September 2025, the company announced Emma Walmsley was stepping down as chief executive at the beginning of 2026, with Luke Miels appointed as her replacement.

Competitive Landscape

Pro stress-test →

AstraZeneca, Novartis, Merck & Co., Pfizer, and Johnson & Johnson are among GSK's primary competitors. GSK competes as a top-10 pharma player with particular strength in vaccines and specialty medicines, though faces competitive pressures from larger peers and specialized biotech companies in oncology and immunology.

Industry Context

GSK plc operates in Pharmaceutical and Biotechnology.

Key facts

Founded: 2000 · Headquarters: London, UK · Employees: 69,400 · Revenue: $42B · Market cap: $118B

What the analysts stress-tested

The top findings that survived the multi-agent debate for GSK plc.

  • Strong vaccine portfolio leadership with regulatory approvals continuing (Priorix MMR approved; camlipixant anticipated 2026 launch)
  • Active M&A strategy with $2.2B Rapt Therapeutics deal (Jan 2026) and Syndivia prostate cancer drug acquisition
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Acquired Rapt Therapeutics for $2.2 billion to expand immunology portfolio
  • October 2025Acquired prostate cancer drug rights from Syndivia for £268 million
  • +1 moreTrack every material event for GSK plc as it happens. Explore monitoring →
Get alerted when GSK plc has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

OncologyLeading oncology and diagnostics→VaccinesMajor vaccine competitor→PharmaceuticalsTop pharma with diverse portfolio→Specialty PharmaGlobal specialty pharmaceutical leader→Respiratory/HIVCompeting in respiratory and specialty pharma→

Compare GSK plc with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

GSK plc operates in Pharmaceutical and Biotechnology. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceutical and Biotechnology research →
NEW · MCP server

Ask your AI assistant about GSK plc

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare GSK plc and its top competitor on Cyborg Score”
“What did GSK plc do this quarter?”
“Is GSK plc a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does GSK plc do?+
GSK plc is a British multinational pharmaceutical and biotechnology company that discovers, develops, and delivers medicines and vaccines. In the pharmaceutical industry, GSK ranks as one of the largest firms by total...
What is GSK plc's Cyborg Score?+
GSK plc has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are GSK plc's main competitors?+
Named competitors include Oncology, Vaccines, Pharmaceuticals, Specialty Pharma. The full competitive landscape is in the AskCyborg report.
How can I get the full GSK plc research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the GSK plc research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track GSK plc over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceutical and Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Gedeon Richter Plc.7GSK plc7Pfizer Inc.